Pharmaxis shares dive 30% on trial results
Pharmaceutical company, Pharmaxis (ASX:PXS) underwhelmed the market with the results from their phase III clinical trial of cystic fibrosis treatment drug Bronchitol®.
Pharmaceutical company, Pharmaxis (ASX:PXS) underwhelmed the market with the results from their phase III clinical trial of cystic fibrosis treatment drug Bronchitol®.